[go: up one dir, main page]

ECSP066860A - Formulaciones de matriz oral que comprenden licarbazepina - Google Patents

Formulaciones de matriz oral que comprenden licarbazepina

Info

Publication number
ECSP066860A
ECSP066860A EC2006006860A ECSP066860A ECSP066860A EC SP066860 A ECSP066860 A EC SP066860A EC 2006006860 A EC2006006860 A EC 2006006860A EC SP066860 A ECSP066860 A EC SP066860A EC SP066860 A ECSP066860 A EC SP066860A
Authority
EC
Ecuador
Prior art keywords
licarbazepina
matrix formulations
oral matrix
oral
formulations
Prior art date
Application number
EC2006006860A
Other languages
English (en)
Inventor
Oskar Kalb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0406379A external-priority patent/GB0406379D0/en
Priority claimed from GB0406738A external-priority patent/GB0406738D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066860A publication Critical patent/ECSP066860A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas que comprenden 10,11-dihidro-10-hidroxi-5H-dibenz[b,f]azepin-5-carboxamida (también referida como "licarbazepina") como sustancia de fármaco.
EC2006006860A 2004-03-22 2006-09-19 Formulaciones de matriz oral que comprenden licarbazepina ECSP066860A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0406379A GB0406379D0 (en) 2004-03-22 2004-03-22 Organic compounds
GB0406738A GB0406738D0 (en) 2004-03-25 2004-03-25 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP066860A true ECSP066860A (es) 2006-11-24

Family

ID=34961345

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006860A ECSP066860A (es) 2004-03-22 2006-09-19 Formulaciones de matriz oral que comprenden licarbazepina

Country Status (16)

Country Link
US (1) US20070196488A1 (es)
EP (1) EP1732519A1 (es)
JP (1) JP2007529564A (es)
AR (1) AR048318A1 (es)
AU (1) AU2005226910B2 (es)
BR (1) BRPI0509067A (es)
CA (1) CA2558787A1 (es)
EC (1) ECSP066860A (es)
IL (1) IL177826A0 (es)
MA (1) MA28527B1 (es)
MX (1) MXPA06010810A (es)
NO (1) NO20064808L (es)
PE (1) PE20051156A1 (es)
RU (1) RU2006137330A (es)
TW (1) TW200534844A (es)
WO (1) WO2005092294A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
PE20060124A1 (es) * 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
EP2380574A1 (en) * 2005-05-06 2011-10-26 Bial-Portela & CA, S.A. Eslicarbazepine acetate and methods of use
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) * 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
WO2012120356A2 (en) 2011-03-08 2012-09-13 Jubilant Life Sciences Limited Process for the preparation of (s)-(+)-or (r)-(-)-10 hydroxy dihydrodibenz[b,f]azepines by enantioselective reduction of 10, 11-dihydro-10-oxo-5h-dibenz[b,f]azepines and polymorphs thereof
EP2498481A1 (en) 2011-03-09 2012-09-12 Sensirion AG Mobile phone with humidity sensor
JP2013237676A (ja) * 2013-06-26 2013-11-28 Bial-Portela & Ca Sa 酢酸エスリカルバゼピン及び使用方法
EP3957302A1 (en) 2015-12-18 2022-02-23 Jubilant Generics Limited Solid oral dosage forms of eslicarbazepine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
AU2003240654A1 (en) * 2002-05-31 2003-12-19 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
AU2003266965A1 (en) * 2002-08-06 2004-02-25 Novartis Ag Use of carboxamides for the treatment of tinnitus
PE20060124A1 (es) * 2004-03-22 2006-03-07 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina

Also Published As

Publication number Publication date
MXPA06010810A (es) 2006-12-15
AU2005226910B2 (en) 2009-06-04
TW200534844A (en) 2005-11-01
JP2007529564A (ja) 2007-10-25
IL177826A0 (en) 2006-12-31
PE20051156A1 (es) 2006-02-13
AR048318A1 (es) 2006-04-19
AU2005226910A1 (en) 2005-10-06
NO20064808L (no) 2006-12-15
BRPI0509067A (pt) 2007-08-21
EP1732519A1 (en) 2006-12-20
US20070196488A1 (en) 2007-08-23
CA2558787A1 (en) 2005-10-06
WO2005092294A1 (en) 2005-10-06
RU2006137330A (ru) 2008-05-10
MA28527B1 (fr) 2007-04-03

Similar Documents

Publication Publication Date Title
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
BR0015188A (pt) Composições farmacêuticas
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
IL173571A0 (en) Injectable, oral, or topical sustained release pharmaceutical formulations
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
ATE303149T1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
BRPI0620229A8 (pt) formulação
ECSP066872A (es) Tabletas desintegrantes que comprenden licarbazepina
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
ECSP066292A (es) Sistemas semi-sólidos que contienen derivados de azetidina
WO2006138431A3 (en) Methods and pharmaceutical formulations for increasing bioavailability
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
DE602006002328D1 (de) Polysubstituierte 1,1-pyridinyloxycyclopropanamine Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen
TNSN06298A1 (en) Disintegrating tablets comprising licarbazepine
TW200610526A (en) Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents
ECSP045039A (es) Composiciones de disgregación intraoral organolepticamente aceptables
ATE429905T1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung
BRPI0500420A (pt) composição estável para substáncia farmacologicamente ativa